Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.
Prospective research suggests DNA and RNA sequencing can reveal pathogen, microbiome, and host expression features to detect lower respiratory tract infections.
The company is aiming to make its Digital Spatial Profiling technology compatible with NGS and will present customer data from its Hyb & Seq at AGBT.
Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.
The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.
The partners will test samples from an NSABP biobank on Nanostring's platform and with standard IHC to look for newer biomarkers of cancer immune evasion.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.